NCT01558869View on ClinicalTrials.gov

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Capecitabine

1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

DRUG

Oxaliplatin

70 mg/m2 IV on day 1 of a 2-week cycle

DRUG

Irinotecan

130 mg/m2 IV on day 1 of a 2-week cycle

Trial Locations (1)

Unknown

Queen Mary Hospital, The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT01558869 - Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter